Terapia elettroconvulsiva

Electroconvulsive therapy (ECT) is a biomedical treatment that uses brief electrical pulses to induce a controlled seizure lasting about 60 seconds. Patients receive anesthesia and muscle relaxants to prevent physical convulsions and ensure minimal discomfort. The procedure is part of broader treatment strategies for psychological disorders, reducing depression symptoms with approximately 70% of patients showing significant improvement within two to four weeks.

Unilateral ECT places one electrode on the right side of the head and another on top, targeting the brain's right hemisphere. This approach significantly reduces the risk of memory loss and cognitive impairment compared to bilateral ECT, which places electrodes on both sides of the head. Modern unilateral stimulation has made ECT safer while maintaining its therapeutic effectiveness for severe depression.

ECT's origins trace back to Hippocrates, who observed that malaria-induced convulsions sometimes alleviated mental illness. Modern ECT was developed in 1938 by Italian neurologist Ugo Cerletti, who introduced the controlled electrical induction method. Early applications lacked anesthesia and caused severe bodily convulsions, but contemporary ECT has evolved into a refined, safer procedure with protective medications.

ECT is primarily used for individuals with severe, treatment-resistant depression who do not respond to medication or psychotherapy. It is particularly effective for cases involving acute suicidality, offering rapid mood improvement and life-saving relief. The procedure provides faster results than other interventions, making it valuable for patients at high suicide risk who need immediate symptom relief.

ECT remains controversial primarily due to memory loss and cognitive impairment, though modern protocols have reduced these risks. Patients may experience temporary memory gaps and cognitive effects, and long-term efficacy concerns exist since some patients relapse into depression. Despite these drawbacks, many clinicians argue that ECT's life-saving benefits for severe depression outweigh the potential risks when other treatments fail.

ECT reduces overactivity in brain regions associated with depression and potentially stimulates neurogenesis, promoting the growth of new neurons and synaptic connections. These neurobiological changes contribute to rapid mood improvement. The seizure activity triggered by electrical stimulation appears to reset abnormal brain patterns, offering relief within two to four weeks of treatment, typically administered three times per week.

During ECT, a brief electrical pulse lasting less than a second is delivered through scalp electrodes, triggering a seizure lasting approximately 60 seconds. Patients are unconscious under anesthesia and muscle relaxants, preventing physical convulsions. Recovery occurs within 30 minutes, and patients awaken with no memory of the treatment, allowing them to resume normal activities quickly.